Cardiovascular Diseases, NSTEMI, STEMI
Conditions
Brief summary
The overall objective of the Cholesterol Lowering via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome ACS (CLEAR ACS) study is to determine the efficacy, safety, and tolerability of bempedoic acid/ezetimibe (BA/E) in a contemporary and real-world population, enriched for older adults, women, and underrepresented racial/ethnic groups, of adults with a recent acute coronary syndrome (ACS) event independent of use of statin therapy before the ACS event.
Detailed description
The CLEAR ACS study is a prospective, virtual, electronic health record (EHR)-based, randomized, double-blind, placebo-controlled, parallel-group, pragmatic clinical trial (PCT) embedded within Kaiser Permanente Northern California's fully integrated and learning health care delivery system. The EHR will be screened in real-time for potentially eligible participants across all Kaiser Permanente Northern California hospitals using validated diagnostic and procedural codes, disease registries, laboratory values, pharmacy dispensing information, and sociodemographic data sources. Eligible patients that provide informed consent will be randomized in a 1:1 allocation ratio to an initial 12 weeks of blinded bempedoic acid/ezetimibe (BA/E) vs. matching placebo followed by a 12-week open-label extension phase where all patients will receive open-label, unblinded bempedoic acid/ezetimibe.
Interventions
DRUGBempedoic Acid / Ezetimibe Oral Tablet
Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
DRUGPlacebo
Matching placebo by mouth once daily for 12 weeks
Sponsors
Esperion Therapeutics, Inc.
Kaiser Permanente
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Pragmatic randomized clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women age \>18 years * Able to provide informed consent * A documented recent ACS event (i.e., defined as up to 14 days post-discharge from an index hospitalization for a non-ST-elevation MI \[NSTEMI\] or ST-elevation MI \[STEMI\] necessitating urgent and/or emergent percutaneous coronary intervention \[PCI\] and/or coronary after bypass graft \[CABG\]) * At least 6 months of continuous health plan membership and prescription drug benefit prior to enrollment * A registered e-mail address with Kaiser Permanente in order to obtain electronic consent (eConsent) for study participation
Exclusion criteria
* Receipt of BA/E on or within 3 months before the day of enrollment * A history of hypersensitivity to BA/E * Women who are pregnant or planning to become pregnant and/or breastfeeding mothers * A diagnosis of gout and/or previously known laboratory-confirmed hyperuricemia (serum uric acid \>8.0 mg/dL) * A history of tendon disorders or tendon rupture * Current and/or planned treatment with simvastatin/pravastatin, cyclosporine, fibrates, and/or bile acid sequestrants (to avoid drug-drug interactions) * A known life-limiting diagnosis (e.g., stage D heart failure, severe liver disease, end-stage kidney disease \[ESKD\] requiring chronic dialysis or an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, metastatic cancer and/or actively receiving systemic chemotherapy) * Institutionalized and/or receiving palliative care * Non-English speaking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the efficacy of BA/E vs. matching placebo on LDL-C level following a recent ACS event. | 0-12 weeks | Percent (%) change from baseline to week 12 in LDL-C level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the efficacy of BA/E vs. matching placebo on the lipid profile following a recent ACS event. | 0-12 weeks | \- Percent (%) change from baseline to week 12 in high-density lipoprotein cholesterol (HDL-C) |
Other
| Measure | Time frame | Description |
|---|---|---|
| To assess the safety and tolerability of BA/E vs. matching placebo following a recent ACS event. | 0-12 weeks | \- Proportion (%) of adverse events (AEs) leading to permanent study drug discontinuation and unexpected serious AEs (SAEs) at 12 weeks |
| To explore the clinical effectiveness of BA/E vs. usual care on all-cause and cause-specific morbidity and mortality following a recent ACS event. | 0-12 weeks | \- Rate (# of events per 100 person-years) of all-cause mortality (ACM) |
Countries
United States
Contacts
Primary ContactAndrew P Ambrosy, MD
Backup ContactAlan S Go, MD
Outcome results
None listed